Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This triplet study is an IST so USCF will be paying for it. More inportantly is that Merck is very interested in testing TAVO in expanded combinations. They are obviously very interested in the potential Oncosec has. Duke University will be starting pre-clinical work with TAVO in combo with vaccines. The future for Keytruda expansion will be combo therapie. TAVO will eventually be targeting frontline therapy. All we need is PISCES to get an AA next year and Oncosec's platform will be validated....Merck will know the FDA is willing to give the thumbs up for TAVO. Green sky ahead for those who care to hang in here.
this stock is nuts.....gaping up now. If we see green today I hope it holds. Market manipulation at its finest. Long Oncosec......need some respect already for great science they are bringing.
I hope Oncosec was selling shares to Aspire at higher prices pre-market. Seems like the structure of their deal with Aspire was to take advantage of spikes like we had today on news.....this could explain why we had a continued decline after the spike. % million in volume today is alot of volume, we will see if any filings pop up soon.
TNBC data coming soon. Oncosec has plenty of cash on hand, no debt. Alpha Holdings is increasing their stake to 20% + a controlled share offering with Aspire will bring in extra money as needed while we wait for PISCES AA next year.
short sellers out....time for the real move back up on fundamentals. The 100 day SMA sits at .66, I think we solidly finish above that today. After that, the 200 day is 1.03....we got this. I am holding long.
I do believe Oncosec and Merck will do a combo study in lung cancer. Liver and pancreatic cancer will be first on the agenda for the new VLA tech....but with lung cancer being such a huge market Merck would have alot to gain if they did do one.
ASCO would be nice.....and then complete data at SITC in the fall.
ONCS is spring-loaded now. ready to go higher.....has been flagging, chart looks good. AACR and KOL Symposium were very positive. Next-Gen tech is awesome. I see a licensing deal for it soon. PISCES will get AA next year. TNBC data very soon. I added more this morning. Point72 still holding 1.2 million shares of ONCS....they still see the potential here. Too the moon....soon.
Alpha posted it yesterday, I guess they don't care about leaking information. I hope Oncosec is going to be there. They highlight disruptive tech at this venue.
This is not confirmed yet but according to the Alpha Holdings website Oncosec will be at:
Cleveland Clinic Medical Innovation Summit
Save the Date for MIS2019:
October 21-23, 2019
Oncosec may have new involvement with the Cleveland Clinic for drug development.
Digipath, Inc. (DIGP) supports the cannabis and hemp industry’s best practices for reliable testing, data acquisition, cannabis education and training, and brings unbiased cannabis news coverage to the cannabis industry. Digipath Labs provides pharmaceutical-grade analysis and testing to the cannabis and hemp industry to ensure producers, consumers, and patients know exactly what is in the cannabis and hemp they ingest and to help maximize the quality of its client’s products through analysis, research, development, and standardization. Digipath, Inc. and Hemp, Inc. has entered into an agreement for Digipath to install a state of the art testing lab in all of Hemp, Inc.’s locations starting with the Medford, Oregon Local Processing Center. The second one will be installed at their hemp processing facility in Spring Hope, NC and the third one at the hemp grow-off in Golden Valley, Arizona. CEO Todd Denkin is also scheduled to speak at the upcoming Hemp University seminar.
Digipath recently announced that the HEMP INC. site in Oregon would be the first to have a Digipath Lab opened. Also sounds like a site in California is going to be opened soon and one in Colombia by end of year.
I wonder how much revenue Digipath could see from test kits? Any revenue is good revenue in my book.
DIGIPATH INC. ANSWERS DEA CALL FOR FIELD CANNABIS DRUG-TYPE TEST https://digipathlabs.com/news/digipath-inc-answers-dea-call-for-field-cannabis-drug-type-test/?utm_source=twitter.com&utm_medium=social&utm_campaign=digipath-inc.-answers-dea-call-for-field
Good plan indeed. Good luck.
Solid information here. Just for the heck of it I compared GBLX to DIGP, oustanding shares in GBLX are 5x greater at GBLX. As penny stocks go Digipath looks like a real steal right now. This could run to $1 soon. GBLX had a massive run to over $1 a year ago up from the .20 range like where DIGP is right now.
Digipath Inc. is a very interesting play in the cannabis sector. They have alot going on this year. Definitely worth an investment right now.
open market buys last week from both the CEO and CFO is good. The stock options awarded recently mean that Digipath is expected to do well this year I think.
Digipath has 46.93M shares outstanding. When the right news hits, this will fly. Such low volume in this means nothing regarding the price fluctuations 10% up or down. Digipath ambitions to open multiple labs this year will be a stock mover. I am holding tight with my shares. Lab testing is a completely underestimated sector in cannabis. The Farm Bill legalized Hemp so HEMP INC. and Digipath are going to do well in their partnership.
I don't even expect Oncosec to use the Cantor ATM, the new one with Aspire is better for them at this time, the Cantor ATM would have been good to use at the $2 level, not now.
With this ATM Oncosec is at least retaining tight control over the selling of shares to take advantage of better stock pricing on any pop. It is too bad Oncosec did not utilize the Cantor ATM before SITC at $2....that would have yielded very littel dilution and the current ATM with Aspire would not be happening. You can't win them all....data will rule out in the end.
Looks like Aspire will be the lucky recipient of discounted shares right now. If Oncosec is selling shares on this stock pop, let's just get the raise out of the way and let the market focus on data and not worry about cash for a while. Yesterdays AACR poster presentation is very positive for Oncosec going forward.
Also to consider....Oncosec has pre-clinical collaborations with Avacta, Jounce, and others through their TAP program. This is undisclosed research being done. Connections, connections, connections.....out of the blue the unexpected can happen at any time.
Yesterday's data at AACR spelled out the potential. The new multi-gene construct is a next-generation improvement over Oncosec's current platform. I think they could see a licensing deal from this with the announcement of a new pipeline similar to what Jounce/Celgene did. Could spell big money at any time really. If it happens it happens, if not I am confident PISCES will get an approval next year and we are looking at a much higher share price anyway.
If the market is forward-looking then Oncosec should have a much higher market cap based on the prospects of their multi-gen construct. Immunotherapy is advancing and Oncosec is in a solid position to disrupt current markets in oncology. PISCES approval alone should get them to a much higher valuation. TNBC data in a few months, 25 patient data. TNBC could be very big for Oncosec if the data is decent. Early indications are that it will be good.
a sincerely think that Oncosec will have the stock above $1 soon and will not need to do a R/S.
the difference is that Advaxis had multiple clinical holds that killed their stock. They also traded up to $30 like Jounce before they also droppd the ball. In my mind it is batter up time for Oncosec.
haha! If Oncosec hits $30 I will glady cash it out. Their tech works so I doubt it would crash....likely get the buyout way before. Good luck to all Oncosec longs...I mean way way way longs here. Time to retire this investment with a buyout deal.
what the market is not yet factoring in with this potentially game-changer new multi-gene construct is an unexpected infusion of cash via;exclusive licensing deal from Big Pharma or Big Biotech. Example; Jounce landed a major licensing deal with Celgene on pre-clinical findings.....Jounce stock last year hit $30 before crashing. I would welcome that kind of action in Oncosec's near future.
actually Jeff, I think we see $2 very soon. The AACR presentation is a game-changer. The shares will start to move quickly.
the multi-gene construct takes Oncosec to the next level. Merck needs to buy Oncosec or sign a licensing deal now.
Heading back above $1 very soon Jeff.
DAMN...look at the gap now!
HEMP INC. up today. What is good for HEMP INC. is also good for Digipath Inc.
HEMP INC. looking good today. Digipath Inc. will be opening a testing lab at every HEMP INC. location. Both companies looking good. Forbes exposure today sparking a move here.
Oncosec should be on Merck's buyout list. Merck has recently closed on a few small acquisitions, IMDZ closed today....Merck is in the hunt for discounted bios.
Gargosky has Big Pharma experience...she was never out of the picture apparently regarding Oncosec interests. Maybe Alpha Holdings will hire her as the Chief Scientiffic Officer for AlphaBio Labs.
Chief Scientiffic Officer to Oncosec before current one....Malloy.
Gargosky will be consulting for Alpha Holdings subsidiary in California (AlphaBio Labs)....very interesting development!
HEMP INC. and Digipath Inc. FORBES publicity today. $HEMP $DIGP Hemp, Inc. CEO Bruce Perlowin Featured in Forbes Discussing Tobacco Farmers Who are Turning to Industrial Hemp OTC Markets:HEMP https://menafn.com/1098333819/Hemp-Inc-CEO-Bruce-Perlowin-Featured-in-Forbes-Discussing-Tobacco-Farmers-Who-are-Turning-to-Industrial-Hemp-OTC-MarketsHEMP?src=Rss